Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Purple Biotech Ltd ADR (NQ: PPBT ) 0.3730 +0.0084 (+2.30%) Streaming Delayed Price Updated: 3:58 PM EDT, Jul 19, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 86,428 Open 0.3700 Bid (Size) 0.3500 (1) Ask (Size) 0.3740 (10) Prev. Close 0.3646 Today's Range 0.3600 - 0.3900 52wk Range 0.3120 - 1.800 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Purple Biotech to Host Virtual KOL Event to Discuss Positive Interim Results from Phase 2 Pancreatic Cancer Study with CM24 on July 11, 2024 July 10, 2024 From Purple Biotech Ltd. Via GlobeNewswire Purple Biotech Announces Closing of Exercise of Warrants for $2 Million Gross Proceeds July 02, 2024 From Purple Biotech Ltd. Via GlobeNewswire Performance YTD -51.60% -51.60% 1 Month -23.44% -23.44% 3 Month -18.02% -18.02% 6 Month -42.62% -42.62% 1 Year -68.92% -68.92% More News Read More Why Purple Biotech (PPBT) Shares Are Trading Lower July 01, 2024 Via Benzinga Purple Biotech Announces Exercise of Warrants for $2 Million Gross Proceeds July 01, 2024 From Purple Biotech Ltd. Via GlobeNewswire Purple Biotech Reports Additional Positive Interim Results from its Randomized Phase 2 Pancreatic Cancer Study with CM24 Regarding a Potential Predictive Biomarker for Overall Survival Benefit June 27, 2024 From Purple Biotech Ltd. Via GlobeNewswire 12 Health Care Stocks Moving In Tuesday's Pre-Market Session June 11, 2024 Via Benzinga 12 Health Care Stocks Moving In Monday's After-Market Session June 10, 2024 Via Benzinga Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and other Efficacy Endpoints in Pancreatic Cancer June 01, 2024 From Purple Biotech Ltd. Via GlobeNewswire 12 Health Care Stocks Moving In Friday's Intraday Session May 31, 2024 Via Benzinga 12 Health Care Stocks Moving In Thursday's After-Market Session May 23, 2024 Via Benzinga 12 Health Care Stocks Moving In Thursday's Intraday Session May 23, 2024 Via Benzinga PPBT Stock Earnings: Purple Biotech Beats EPS for Q1 2024 May 21, 2024 Via InvestorPlace 12 Health Care Stocks Moving In Friday's After-Market Session May 10, 2024 Via Benzinga Purple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting April 25, 2024 From Purple Biotech Ltd. Via GlobeNewswire 12 Health Care Stocks Moving In Monday's After-Market Session April 22, 2024 Via Benzinga Purple Biotech to Present New Data On its Oncology Drug NT219 at AACR 2024 March 28, 2024 From Purple Biotech Ltd. Via GlobeNewswire Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technology March 14, 2024 From Purple Biotech Ltd. Via GlobeNewswire PPBT Stock Earnings: Purple Biotech Meets EPS for Q4 2023 March 05, 2024 Via InvestorPlace Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024 February 27, 2024 From Purple Biotech Ltd. Via GlobeNewswire Purple Biotech Convenes a Head & Neck Cancer Scientific Advisory Board in Preparation for NT219 Phase 2 Trial February 13, 2024 From Purple Biotech Ltd. Via GlobeNewswire Purple Biotech Reaches Recommended Phase 2 Dose for NT219 February 01, 2024 From Purple Biotech Ltd. Via GlobeNewswire 12 Health Care Stocks Moving In Wednesday's After-Market Session January 10, 2024 Via Benzinga Purple Biotech Appoints Dr. Yael Margolin to its Board of Directors December 20, 2023 From Purple Biotech Ltd. Via GlobeNewswire Purple Biotech Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trial December 14, 2023 From Purple Biotech Ltd. Via GlobeNewswire 12 Health Care Stocks Moving In Monday's Pre-Market Session December 11, 2023 Via Benzinga Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
